> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rothblatt Plans To Sell $71.5 Million Of United Therapeutics Stock After 64 Sales In Three Months
- URL: https://www.bullished.co/rothblatt-plans-to-sell-71-5-million-of-united-therapeutics-stock-after-64-sales-in-three-bdd6e428/
- Published: 2026-11-02T21:46:13.000Z
- Updated: 2026-11-02T21:46:13.000Z
- Description: The CEO's next planned sale is 119,410 shares, on top of 608,000 shares already sold for $319,182,640 under a pre-set trading plan.
- Author: Matteo Parrino
- Tags: Insider Trades, UTHR, Industry: Healthcare

[United Therapeutics](https://www.bullished.co/tag/uthr/) Chairperson and CEO Martine Rothblatt plans to sell [119,410 shares](https://www.sec.gov/Archives/edgar/data/0001106578/000195004726010587/xsl144X01/primary%5Fdoc.xml?ref=bullished.co) of the company's common stock, valued at $71.5 million in a Form 144 notice, the SEC filing that announces a planned insider sale, filed Monday. It follows 64 sales in the past three months listed on the same form, which total 608,000 shares and $319,182,640 in gross proceeds.

## A daily 9,500-share routine

Every one of the 64 sales on the form is for 9,500 shares and is labeled a 10b5-1 sale for Rothblatt, meaning a pre-scheduled trading plan filed with the SEC. The first was on August 3 and the most recent on October 30.

The October 30 sale brought in $5,700,856\. Daily proceeds on the form ranged from $4,498,753 on September 24 to that figure, rising as the share price climbed through October.

The new proposed sale is far larger than any single one of those trades: 119,410 shares against 9,500\. The form gives November 2 as the approximate sale date and names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.

## Shares from an option exercise

The form says the shares come from an option exercise paid for in cash on November 2\. Rothblatt would be selling stock she acquires by exercising options, rather than shares she already held outright.

United Therapeutics develops and sells drugs for pulmonary arterial hypertension, a life-threatening disease of the blood vessels in the lungs. Its products include Tyvaso, Remodulin, Orenitram and Adcirca, and Tyvaso made up 59 percent of total revenues for 2025, according to its annual report.

## Stock near its 52-week high

UTHR closed at $596.13 in Monday trading. As of Friday's close, the stock was up 22.9% this year and 32.0% over 12 months, within 5% of its 52-week high of $609.99.

The form allows the sale to take place within about 90 days of filing, so later SEC filings from Rothblatt will show how much was actually sold.

The most recent 9,500-share sale, on October 30, brought in $5,700,856.

### Sources

- [Form 144 — Martine A Rothblatt (UTHR)](https://www.sec.gov/Archives/edgar/data/0001106578/000195004726010587/xsl144X01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on United Therapeutics

- [United Therapeutics Authorizes Another $2 Billion Buyback, Separate From Its Running Repurchase](https://www.bullished.co/united-therapeutics-authorizes-another-2-billion-buyback-separate-from-its-running-53a2e6b6/)
- [Liquidia To Pay United Therapeutics $330.4 Million And Pull Yutrepia's Lung-Disease Label](https://www.bullished.co/liquidia-to-pay-united-therapeutics-330-4-million-and-pull-yutrepias-lung-disease-label-ea223a0f/)

[All United Therapeutics (UTHR) coverage →](https://www.bullished.co/tag/uthr/)